News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

While Amgen (AMGN)-Size Biotechs Run Into Trouble, These Are The Biotechs With The Most Promising Pipelines



6/16/2017 6:43:54 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
The biotech industry, always a highly technical conundrum for investors, might currently pose an even greater challenge — and offer even greater opportunities — than usual.

Early industry innovators like Amgen (AMGN), Biogen (BIIB) and Gilead Sciences (GILD) currently find themselves in "big trouble," according to Loncar Investments Chief Executive Brad Loncar, largely as victims of their own success.

But cancer and rare disease specialists Kite Pharma (KITE) and Bluebird Bio (BLUE) — already sitting atop winning stock runs — could be poised for yet another take off, said Loncar, whose firm launched an ETF in 2015 to track the immuno-oncology market.

Read at News Release


comments powered by Disqus
Amgen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES